@misc{indiciae0dc472f486a2,
  title = {Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.},
  author = {D\&\#xe9;sir\&\#xe9;e van der Heijde and Philip J Mease and Carle Paul and Frank Behrens and Laure Gossec and Yuko Kaneko and Lihi Eder and Laura C Coates and Andrew E Pink and Weiguo Wan and Enrique R Soriano and Piotr Leszczy\&\#x144;ski and Jose U Scher and Atul Deodhar and Chahin Pachai and Janice Li and Xue Fan and Sahar Rabbat and Caroline Sardinas and Eleni Vritzali and John Vaile and Joseph F Merola},
  year = {2026},
  doi = {10.1016/j.ard.2026.05.029},
  url = {https://pubmed.ncbi.nlm.nih.gov/42562758/},
  note = {Source identifier: 42562758}
}